Valuation: Alkermes plc

Market Cap 8.29B 7.18B 6.71B 6.14B 11.55B 790B 11.75B 78.66B 30.86B 395B 31.12B 30.44B 1,320B P/E 2026 *
-97x
P/E 2027 * 67.9x
Enterprise Value 9.03B 7.82B 7.32B 6.69B 12.59B 861B 12.8B 85.72B 33.63B 431B 33.91B 33.17B 1,438B EV / Sales 2026 *
4.95x
EV / Sales 2027 * 4.61x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week+0.84%
Current month+0.84%
1 month-8.14%
3 months+41.18%
6 months+41.79%
Current year+76.55%
1 week 48.21
Extreme 48.21
50.85
1 month 47.66
Extreme 47.66
53.88
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Compliance Officer

-2,034 0.0012%
3/8/26 Fiscal year

Chief Technology Officer

19,000 0.0113%
3/8/26 Fiscal year

Director

133,416 0.0795%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%+0.84%+84.95%+76.11% 8.25B
+1.29%+3.09%+6.43%+18.53% 49.47B
+0.89%+10.37%+491.34%+598.75% 43.97B
+3.08%+13.60%+24.57%+78.98% 39.6B
+1.38%+2.97%+34.54%+10.66% 39.29B
+0.85%+7.66%+21.22%+48.78% 32.43B
+0.08%+4.80% - - 16.84B
+1.99%+4.39%+38.70%+126.93% 16.49B
+0.34%+2.76%+5.39%+20.43% 14.01B
+3.56%+19.13%+86.23%+28.36% 12.77B
Average +1.39%+6.53%+88.15%+111.95% 27.31B
Weighted average by Cap. +1.45%+6.83%+107.14%+139.46%

Financials

2026 *2027 *
Net sales 1.82B 1.58B 1.48B 1.35B 2.54B 174B 2.59B 17.32B 6.8B 87.02B 6.85B 6.7B 291B 1.94B 1.68B 1.58B 1.44B 2.71B 185B 2.76B 18.46B 7.24B 92.73B 7.3B 7.14B 310B
Net income -89.92M -77.9M -72.84M -66.57M -125M -8.57B -127M -853M -335M -4.29B -338M -330M -14.32B 120M 104M 97.44M 89.05M 168M 11.46B 170M 1.14B 448M 5.74B 452M 442M 19.16B
Net Debt 744M 644M 603M 551M 1.04B 70.89B 1.05B 7.06B 2.77B 35.48B 2.79B 2.73B 118B 670M 580M 543M 496M 934M 63.84B 950M 6.36B 2.49B 31.95B 2.52B 2.46B 107B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
10/08/26 USD 49.40 +0.47% 1,511,241
07/08/26 USD 49.17 +1.65% 1,110,968
06/08/26 USD 48.37 -2.50% 1,569,088
05/08/26 USD 49.61 -0.12% 1,706,769
04/08/26 USD 49.67 +0.28% 1,430,842
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.40USD
Average target price
56.00USD
Spread / Average Target
+13.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock